rs11570112
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000256.3(MYBPC3):c.2992C>T(p.Gln998*) variant causes a stop gained, splice region change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 2/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000256.3 stop_gained, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MYBPC3 | NM_000256.3 | c.2992C>T | p.Gln998* | stop_gained, splice_region_variant | 28/35 | ENST00000545968.6 | NP_000247.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MYBPC3 | ENST00000545968.6 | c.2992C>T | p.Gln998* | stop_gained, splice_region_variant | 28/35 | 5 | NM_000256.3 | ENSP00000442795.1 | ||
MYBPC3 | ENST00000399249.6 | c.2992C>T | p.Gln998* | stop_gained, splice_region_variant | 27/34 | 5 | ENSP00000382193.2 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 33
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Apr 21, 2014 | This mutation is denoted p.Gln998Stop (CAG>TAG): c.2992 C>T in exon 28 of the MYBPC3 gene (NM_000256.3). The Q998X mutation in the MYBPC3 gene has been reported in at least one patient with HCM (Millat G et al., 2010). Millat et al. (2010) report that the Q998X mutation was not seen in 200 control individuals. Furthermore, the Q998X mutation was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. Additionally, Q998X is predicted to cause loss of normal protein function either by protein truncation or nonsense-mediated mRNA decay. Other nonsense mutations in the MYBPC3 gene have been reported in association with HCM. In summary, Q998X in the MYBPC3 gene is interpreted as a disease-causing mutation. The variant is found in HCM panel(s). - |
Hypertrophic cardiomyopathy Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 19, 2020 | For these reasons, this variant has been classified as Pathogenic. Loss-of-function variants in MYBPC3 are known to be pathogenic (PMID: 19574547). This variant has been observed in individual(s) with hypertrophic cardiomyopathy (PMID: 20624503). ClinVar contains an entry for this variant (Variation ID: 180993). This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Gln998*) in the MYBPC3 gene. It is expected to result in an absent or disrupted protein product. - |
Cardiovascular phenotype Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 03, 2023 | The p.Q998* pathogenic mutation (also known as c.2992C>T), located in coding exon 28 of the MYBPC3 gene, results from a C to T substitution at nucleotide position 2992. This changes the amino acid from a glutamine to a stop codon within coding exon 28. This alteration has been reported in hypertrophic cardiomyopathy cohorts and a sudden cardiac death cohort (Millat G et al. Eur J Med Genet, 2010 Jul;53:261-7; Helms AS et al. Circ Genom Precis Med, 2020 Oct;13:396-405; Guo L et al. JAMA Cardiol, 2021 Sep;6:1013-1022). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at